CRIS Stock Summary and Trading Ideas (Curis | NASDAQ:CRIS)

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis trades on the NASDAQ stock market under the symbol CRIS.

As of July 21, 2026, CRIS stock price climbed to $4.75 with 48,938 million shares trading.

CRIS has a beta of 5.41, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.06 to the broad based SPY ETF.

CRIS has a market cap of $9.26 million. This is considered a Sub-Micro Cap stock.

Last quarter Curis reported $0 in Revenue and -$1.25 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.98.

In the last 3 years, CRIS traded as high as $17.49 and as low as $.18.

The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VTI, VXF.

CRIS has outperformed the market in the last year with a return of +163.9%, while the SPY ETF gained +20.4%. In the last 3 month period, CRIS beat the market returning +670.0%, while SPY returned +5.9%. However, in the most recent 2 weeks CRIS has underperformed the stock market by returning -20.0%, while SPY returned -0.4%.

CRIS support price is $3.99 and resistance is $5.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS shares will trade within this expected range on the day.